EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH
(EEJSAR) ISSN: 2992-4146
©EEJSAR Publications Volume 7 Issue 3 2025

The Role of Second Messengers in Neurodegenerative Disorders

Gakire Munyaneza H.

Faculty of Engineering Kampala International University Uganda

ABSTRACT

Neurodegenerative disorders (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) are a group of progressive and debilitating conditions characterized by the gradual deterioration of neuronal structure, function, and viability. These disorders result in cognitive decline, motor impairment, behavioral abnormalities, and ultimately, significant disability and reduced quality of life. Despite differences in clinical manifestations and affected brain regions, these diseases share common molecular and cellular mechanisms, including mitochondrial dysfunction, oxidative stress, excitotoxicity, protein aggregation, and impaired intracellular signaling. Among the most critical components of neuronal signaling are second messengers—small, diffusible molecules that relay signals from membrane-bound receptors to intracellular targets, orchestrating a wide range of cellular responses. Emerging evidence implicates the dysregulation of second messenger systems as a central contributor to the pathogenesis and progression of NDs. This review focuses on key second messengers implicated in neurodegeneration, including calcium ions (Ca^{2+}), cyclic nucleotides (cAMP, cGMP), inositol 1,4,5-trisphosphate (IP_3), diacylglycerol (DAG), and reactive oxygen and nitrogen species (ROS/RNS). We explore their physiological roles in neuronal homeostasis, synaptic function, and plasticity, as well as the consequences of their pathological dysregulation. Furthermore, we highlight current and emerging therapeutic strategies targeting these signaling pathways to mitigate neurodegenerative processes.

Keywords: second messengers, calcium, cAMP, cGMP, neurodegeneration, Alzheimer's disease, Parkinson's disease, oxidative stress, phosphodiesterases, signal transduction

INTRODUCTION

Neurodegenerative diseases (NDs) comprise a diverse group of chronic, progressive conditions characterized by the selective loss of structure and function of neurons in specific regions of the central nervous system (CNS) [1] Common disorders in this category include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) [2] These diseases are often associated with debilitating cognitive, behavioral, and motor impairments, ultimately leading to a decline in quality of life and increased dependency [3] Although each neurodegenerative disorder presents with distinct clinical features and underlying genetic and environmental factors, they often share convergent pathophysiological mechanisms [4] A hallmark of many NDs is the accumulation of misfolded and aggregated proteins, such as amyloid-beta and tau in AD, alpha-synuclein in PD, and mutant huntingtin in HD. These aggregates interfere with normal cellular processes, including mitochondrial function, autophagy, axonal transport, and synaptic integrity. Mitochondrial dysfunction and oxidative stress are also commonly observed, resulting in impaired energy metabolism and increased vulnerability to apoptosis [5] Another critical and increasingly recognized contributor to neurodegeneration is the disruption of intracellular signaling cascades that maintain neuronal survival, plasticity, and communication [6]. Second messengers—such as calcium ions (Ca^{2+}), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), inositol 1,4,5-trisphosphate (IP_3), diacylglycerol (DAG), and reactive oxygen and nitrogen species (ROS/RNS)—play vital roles in transducing extracellular signals into precise intracellular responses [7]. In neurons, these messengers regulate synaptic transmission, neurotrophic support, gene expression, and adaptive responses to environmental stimuli. Dysregulation of second messenger signaling can

disrupt these essential functions, leading to aberrant neuronal communication, inflammation, and cell death [8,9] Understanding the intricate role of second messengers in neurodegenerative processes not only offers insight into disease mechanisms but also unveils novel targets for early diagnosis and therapeutic intervention.

Major Classes of Second Messengers in the Nervous System

Neurons rely heavily on tightly regulated intracellular signaling to respond rapidly and appropriately to extracellular cues. Second messengers are key intermediates that translate surface receptor activation into precise cellular responses [10] In the context of neurodegeneration, dysregulation of these messengers contributes to synaptic dysfunction, mitochondrial stress, and neuronal death. This section outlines the major classes of second messengers relevant to the nervous system and their roles in neurodegenerative pathology.

Calcium Ions (Ca^{2+})

Calcium ions serve as ubiquitous and highly dynamic second messengers, regulating processes such as neurotransmitter release, synaptic plasticity, gene transcription, and apoptosis [11] In healthy neurons, intracellular Ca^{2+} levels are tightly controlled by voltage-gated channels, ligand-gated receptors (e.g., NMDA, AMPA), and intracellular stores in the endoplasmic reticulum (ER) and mitochondria [12] However, in neurodegenerative diseases, this regulation is disrupted. For instance, in Alzheimer's disease (AD), amyloid-beta (Aβ) oligomers overstimulate NMDA receptors, causing sustained Ca^{2+} influx and ER stress, which impairs neuronal function and survival. In Parkinson's disease (PD), α-synuclein aggregates disturb calcium buffering in dopaminergic neurons, exacerbating mitochondrial damage and oxidative stress [13]

Cyclic Nucleotides (cAMP and cGMP)

The cyclic nucleotides cAMP and cGMP play central roles in modulating neuronal excitability, synaptic plasticity, long-term potentiation (LTP), and neurotrophic support [14] They act through downstream effectors like protein kinase A (PKA) and protein kinase G (PKG), which regulate transcription factors such as CREB (cAMP response element-binding protein) [15] In AD and Huntington's disease (HD), impaired cAMP/PKA signaling correlates with reduced CREB activity and diminished neuroprotective gene expression. Conversely, pharmacological elevation of cGMP through phosphodiesterase inhibitors has demonstrated neuroprotective and cognitive-enhancing effects in experimental models of AD, making it a promising therapeutic avenue [16]

Inositol 1,4,5-Trisphosphate (IP_3) and Diacylglycerol (DAG)

IP_3 and DAG are lipid-derived second messengers generated via the activation of phospholipase C (PLC) by G protein-coupled receptors and receptor tyrosine kinases [17] IP_3 facilitates Ca^{2+} release from the ER, while DAG activates protein kinase C (PKC), influencing gene expression, cytoskeletal dynamics, and synaptic strength. Aberrant PLC-IP_3 signaling has been implicated in synaptic loss and network dysfunction in AD. Meanwhile, alterations in DAG-PKC pathways are associated with increased tau phosphorylation, glial activation, and pro-inflammatory signaling in multiple NDs [18]

Reactive Oxygen and Nitrogen Species (ROS/RNS)

Reactive oxygen species (e.g., superoxide, hydrogen peroxide) and reactive nitrogen species (e.g., nitric oxide, peroxynitrite) function as redox-sensitive messengers in physiological signaling [19] However, excessive ROS/RNS production under pathological conditions leads to oxidative stress—damaging cellular lipids, proteins, and DNA. In AD and ALS, chronic oxidative stress from mitochondrial leakage or NADPH oxidase activity promotes neuroinflammation, impairs synaptic function, and accelerates neuronal loss [20].

Mechanisms of Dysregulation in Neurodegenerative Diseases

The pathogenesis of neurodegenerative diseases involves multiple intersecting mechanisms that disrupt second messenger signaling [21]. These include the accumulation of toxic protein aggregates, mitochondrial dysfunction, and chronic neuroinflammation—each of which perturbs cellular homeostasis and propagates neuronal injury.

Protein Aggregation and Disrupted Signaling

A hallmark of many neurodegenerative disorders is the accumulation of misfolded proteins that aggregate into toxic oligomers or fibrils. In Alzheimer's disease (AD), amyloid-beta (Aβ) oligomers interact aberrantly with membrane receptors, such as NMDA and nicotinic acetylcholine receptors, leading to excessive calcium influx and excitotoxicity [22] Similarly, α-synuclein aggregates in Parkinson's disease (PD) disrupt synaptic vesicle cycling and impair dopamine signaling. In Huntington's disease (HD), mutant huntingtin interferes with G protein-coupled receptor function and downstream second messenger systems [23] These aggregates also disrupt organelle function, particularly the endoplasmic reticulum (ER) and mitochondria, impairing calcium storage and redox signaling.

Mitochondrial Dysfunction

Mitochondria play a pivotal role in regulating intracellular calcium dynamics and reactive oxygen species (ROS) generation [24]. In neurodegenerative conditions, mitochondrial integrity is compromised, often through the opening of the mitochondrial permeability transition pore (mPTP). This leads to uncontrolled calcium release, increased ROS production, and activation of cell death pathways. Impaired mitochondrial ATP production also hinders the energy-dependent regulation of second messenger cascades [25]

Inflammation and Glial Dysfunction

Activated microglia and astrocytes, the primary immune and support cells of the CNS, release reactive nitrogen species (RNS), ROS, and cytokines in response to neuronal injury [26]. While transient activation is protective, chronic glial activation sustains an inflammatory environment. This persistent pro-inflammatory state alters second messenger dynamics, exacerbating oxidative stress, calcium dysregulation, and synaptic dysfunction, thereby fueling the progression of neurodegeneration [27].

Therapeutic Targeting of Second Messenger Pathways

Given the pivotal role of second messengers in maintaining neuronal function and their dysregulation in neurodegenerative diseases, targeting these pathways offers promising therapeutic avenues [28] Strategies aimed at restoring second messenger balance can mitigate neuronal damage and improve cognitive and motor outcomes.

Calcium Channel Modulators

Excessive calcium influx is a hallmark of excitotoxicity in conditions like Alzheimer's disease (AD). Memantine, an NMDA receptor antagonist, mitigates Ca^{2+}-mediated excitotoxicity without significantly impairing physiological neurotransmission and is clinically approved for moderate to severe AD [11]. Beyond NMDA receptors, ryanodine receptor (RyR) stabilizers are under investigation for their ability to restore endoplasmic reticulum (ER) calcium homeostasis and reduce ER stress-associated neurotoxicity [13]

Phosphodiesterase Inhibitors

Phosphodiesterase (PDE) inhibitors prevent the breakdown of cyclic nucleotides, thus enhancing cAMP and cGMP signaling. Rolipram (PDE4 inhibitor) boosts PKA/CREB-mediated neuroprotective gene expression, while sildenafil (PDE5 inhibitor) improves synaptic plasticity and cerebral blood flow. Both have demonstrated neuroprotective effects in preclinical models of AD and Parkinson's disease (PD) [29]

Antioxidants and Redox Modulators

Antioxidants such as edaravone (approved for amyotrophic lateral sclerosis) scavenge free radicals, reducing ROS-mediated neuronal injury. NRF2 activators promote endogenous antioxidant defenses, restoring redox balance and limiting second messenger dysregulation in multiple neurodegenerative conditions [30]

Emerging Perspectives

Beyond their classical roles in signal transduction, second messengers have been increasingly recognized for their involvement in broader regulatory processes such as epigenetic modulation, autophagy, and synaptic remodeling [31]. Calcium and cyclic nucleotides, for example, can influence chromatin remodeling and histone modification through signaling to transcriptional regulators, thereby altering gene expression patterns relevant to neuronal survival and plasticity [11] Second messengers also modulate autophagic flux, which is critical for the clearance of aggregated proteins commonly seen in neurodegenerative diseases. Advances in nanotechnology and imaging such as genetically encoded fluorescent nanosensors and high-resolution calcium imaging have enabled real-time visualization of second messenger dynamics in subcellular compartments, deepening our understanding of their spatial and temporal regulation [32] Furthermore, emerging personalized medicine approaches that integrate genomic, proteomic, and metabolomic data are paving the way for individualized therapies [33] By targeting dysregulated second messenger pathways specific to a patient's molecular profile, such strategies hold the potential to enhance treatment efficacy and reduce adverse effects.

CONCLUSION

Second messengers are fundamental to neuronal communication, plasticity, and survival, orchestrating a wide array of cellular responses to external and internal stimuli. Their dysregulation contributes to key pathological processes in neurodegenerative diseases, including excitotoxicity, oxidative stress, impaired gene expression, and inflammation. As such, they represent critical nodes for therapeutic intervention and biomarkers for early disease detection. Advancing our understanding of second messenger signaling through integrative approaches—such as multi-omics, systems neuroscience, and advanced imaging—will be instrumental in decoding the complexity of neurodegenerative networks and developing more precise, mechanism-based strategies for prevention, diagnosis, and treatment.

REFERENCES

1. Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int J Mol Sci. 2022 Feb 6;23(3):1851. doi: 10.3390/ijms23031851. PMID: 35163773; PMCID: PMC8837071.
2. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008 Aug;29(8):357-65. doi: 10.1016/j.it.2008.05.002. Epub 2008 Jul 1. PMID: 18599350; PMCID: PMC4794280.
3. Kharat S, Mali S, Korade G, Gaykar R. Navigating Neurodegenerative Disorders: A Comprehensive Review of Current and Emerging Therapies for Neurodegenerative Disorders. J Neurosci Neurol Disord. 2024; 8: 033-04
4. Xu, Yq., Chen, Y., Xing, Jx. *et al.* Relationship between enriched environment and neurodegeneration: a review from mechanism to therapy. *Clin Epigenet* **17**, 13 (2025). https://doi.org/10.1186/s13148-025-01820-4
5. Agnello L, Gambino CM, Ciaccio AM, Masucci A, Vassallo R, Tamburello M, Scazzone C, Lo Sasso B, Ciaccio M. Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice. *International Journal of Molecular Sciences.* 2024; 25(8):4323. https://doi.org/10.3390/ijms25084323
6. Amartumur, S., Nguyen, H., Huynh, T. *et al.* Neuropathogenesis-on-chips for neurodegenerative diseases. *Nat Commun* **15**, 2219 (2024). https://doi.org/10.1038/s41467-024-46554-8
7. Tanaka M, Toldi J, Vécsei L. Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. *International Journal of Molecular Sciences.* 2020; 21(7):2431. https://doi.org/10.3390/ijms21072431
8. Hu, Z., Luo, Y., Zhu, J. *et al.* Role of the P2 × 7 receptor in neurodegenerative diseases and its pharmacological properties. *Cell Biosci* **13**, 225 (2023). https://doi.org/10.1186/s13578-023-01161-w
9. Wang, Y., Kuca, K., You, L. *et al.* The role of cellular senescence in neurodegenerative diseases. *Arch Toxicol* **98**, 2393–2408 (2024). https://doi.org/10.1007/s00204-024-03768-5
10. Niso-Santano, M., Fuentes, J.M. & Galluzzi, L. Immunological aspects of central neurodegeneration. *Cell Discov* **10**, 41 (2024). https://doi.org/10.1038/s41421-024-00666-z
11. Lee KH, Cha M, Lee BH. Crosstalk between Neuron and Glial Cells in Oxidative Injury and Neuroprotection. *International Journal of Molecular Sciences.* 2021; 22(24):13315. https://doi.org/10.3390/ijms222413315
12. Brini M, Calì T, Ottolini D, Carafoli E. Neuronal calcium signaling: function and dysfunction. Cell Mol Life Sci. 2014 Aug;71(15):2787-814. doi: 10.1007/s00018-013-1550-7. Epub 2014 Jan 19. PMID: 24442513; PMCID: PMC11113927.
13. Pikor D, Hurła M, Słowikowski B, Szymanowicz O, Poszwa J, Banaszek N, Drelichowska A, Jagodziński PP, Kozubski W, Dorszewska J. Calcium Ions in the Physiology and Pathology of the Central Nervous System. *International Journal of Molecular Sciences.* 2024; 25(23):13133. https://doi.org/10.3390/ijms252313133
14. Lisek M, Tomczak J, Boczek T, Zylinska L. Calcium-Associated Proteins in Neuroregeneration. *Biomolecules.* 2024; 14(2):183. https://doi.org/10.3390/biom14020183
15. Su, J., Song, Y., Zhu, Z. *et al.* Cell–cell communication: new insights and clinical implications. *Sig Transduct Target Ther* **9**, 196 (2024). https://doi.org/10.1038/s41392-024-01888-z
16. Elmogheer, S.M.H.M. (2023). Mechanisms of Neuronal Apoptosis and Excitotoxicity. In: Mohamed, E. (eds) Handbook of Neurodegenerative Disorders. Springer, Singapore. https://doi.org/10.1007/978-981-19-3949-5_47-1
17. Wang, B., Zhang, L., Dai, T. *et al.* Liquid–liquid phase separation in human health and diseases. *Sig Transduct Target Ther* **6**, 290 (2021). https://doi.org/10.1038/s41392-021-00678-1
18. Newton AC, Bootman MD, Scott JD. Second Messengers. Cold Spring Harb Perspect Biol. 2016 Aug 1;8(8):a005926. doi: 10.1101/cshperspect.a005926. PMID: 27481708; PMCID: PMC4968160.
19. Kim MJ, Kim E, Ryu SH, Suh PG. The mechanism of phospholipase C-gamma1 regulation. Exp Mol Med. 2000 Sep 30;32(3):101-9. doi: 10.1038/emm.2000.18. PMID: 11048639.
20. Kanemaru K, Nakamura Y. Activation Mechanisms and Diverse Functions of Mammalian Phospholipase C. *Biomolecules.* 2023; 13(6):915. https://doi.org/10.3390/biom13060915

21. Wang Z. Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research. *International Journal of Molecular Sciences.* 2016; 17(1):95. https://doi.org/10.3390/ijms17010095
22. Hussain R, Zubair H, Pursell S, Shahab M. Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. Brain Sci. 2018 Sep 15;8(9):177. doi: 10.3390/brainsci8090177. PMID: 30223579; PMCID: PMC6162719.
23. Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010 Mar;14(3):457-87. doi: 10.1111/j.1582-4934.2010.01010.x. Epub 2010 Jan 11. PMID: 20070435; PMCID: PMC3823450.
24. Park MK, Yang HW, Woo SY, Kim DY, Son D-S, Choi BY, Suh SW. Modulation of Second Messenger Signaling in the Brain Through PDE4 and PDE5 Inhibition: Therapeutic Implications for Neurological Disorders. *Cells.* 2025; 14(2):86. https://doi.org/10.3390/cells14020086
25. Wong, TS., Li, G., Li, S. *et al.* G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. *Sig Transduct Target Ther* **8**, 177 (2023). https://doi.org/10.1038/s41392-023-01427-2
26. Qin J, Ma Z, Chen X, Shu S. Microglia activation in central nervous system disorders: A review of recent mechanistic investigations and development efforts. Front Neurol. 2023 Mar 7;14:1103416. doi: 10.3389/fneur.2023.1103416. PMID: 36959826; PMCID: PMC10027711.
27. Olude MA, Mouihate A, Mustapha OA, Farina C, Quintana FJ, Olopade JO. Astrocytes and Microglia in Stress-Induced Neuroinflammation: The African Perspective. Front Immunol. 2022 May 30;13:795089. doi: 10.3389/fimmu.2022.795089. PMID: 35707531; PMCID: PMC9190229.
28. Singh, D. Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease. *J Neuroinflammation* **19**, 206 (2022). https://doi.org/10.1186/s12974-022-02565-0
29. Sochocka, M., Diniz, B.S. & Leszek, J. Inflammatory Response in the CNS: Friend or Foe?. *Mol Neurobiol* **54**, 8071–8089 (2017). https://doi.org/10.1007/s12035-016-0297-1
30. Kraft AD, Harry GJ. Features of Microglia and Neuroinflammation Relevant to Environmental Exposure and Neurotoxicity. *International Journal of Environmental Research and Public Health.* 2011; 8(7):2980-3018. https://doi.org/10.3390/ijerph8072980
31. Cao R, Tian H, Zhang Y, Liu G, Xu H, Rao G, Tian Y, Fu X. Signaling pathways and intervention for therapy of type 2 diabetes mellitus. MedComm (2020). 2023 Jun 7;4(3):e283. doi: 10.1002/mco2.283. PMID: 37303813; PMCID: PMC10248034.
32. Li B, Ming H, Qin S, Nice EC, Dong J, Du Z, Huang C. Redox regulation: mechanisms, biology and therapeutic targets in diseases. Signal Transduct Target Ther. 2025 Mar 7;10(1):72. doi: 10.1038/s41392-024-02095-6. PMID: 40050273; PMCID: PMC11885647.
33. Pellarin, I., Dall'Acqua, A., Favero, A. *et al.* Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. *Sig Transduct Target Ther* **10**, 11 (2025). https://doi.org/10.1038/s41392-024-02080-z

CITE AS: Gakire Munyaneza H. (2025). The Role of Second Messengers in Neurodegenerative Disorders. EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH, 7(3):76-80